Chronic Hepatitis C Clinical Trial
Official title:
Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C
Verified date | December 2014 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
This study will explore ways to improve the effectiveness of patient Self Management at a
time when genetic test results guide new treatments that will dramatically increase the
possibility of cure of the hepatitis C virus.The study will also focus on the interactions
between provider and patients and the ways that technical work, adaptive work and adaptive
leadership foster patient self-management.This proposed 2 year exploratory mixed-methods 12
longitudinal case study will explore patients' and providers' explanations for how and why
they engage in technical work, adaptive work, and adaptive leadership and the ways in which
these strategies promote or pose barriers to patients' self-management of Chronic Hepatitis
C in the context of the new genetic test results and treatments. Specific aims are to:
1: Examine how technical work, adaptive work and adaptive leadership influence patients'
perceptions of their likelihood of cure and how this work relates to self-management during
12 to 24 weeks of treatment for Chronic Hepatitis C. Research questions are: 1.1) How do
patients describe their interactions with the providers? 1.2) How do these interactions
shape patients' perceptions of the likelihood of cure? 1.3) How do patients' understanding
of their interactions with the provider promote the use of or pose barriers to
self-management during treatment?
AIM 2: Describe providers' use of technical work, and adaptive leadership approaches during
clinical encounters,to include nurse education visits. Research questions are:
2.1) What technical work, and adaptive leadership approaches do providers use when sharing
treatment information with patients during the clinical encounters. 2.2) What explanations
do providers give for how and why they use technical work and adaptive leadership
approaches? AIM 3: Describe the trajectories of illness perceptions(Control/Cure sub-scale -
Illness Perception Scale), symptoms (M.D. Anderson Symptom Inventory) , viral load, and
self-management (Patient Activation Measure) in relation to patient and provider reports of
technical work, adaptive work, and adaptive leadership from the index clinical encounter to
the follow-up treatment response encounter (ranging from 12 to 24 weeks).
Status | Completed |
Enrollment | 20 |
Est. completion date | July 2014 |
Est. primary completion date | July 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - African American or Caucasian - Genotype 1 - Planning to, but have not yet, began treatment for Hepatitis C at Duke University Medical Center or Boice-Willis Clinic in Rocky Mount, NC Exclusion Criteria: - Diagnosed with Bipolar Disorder or Schizophrenia - Not genotype 1 - Any race other than African American or Caucasian. - Hispanic or Latino |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center | Durham | North Carolina |
United States | Boice Willis Clinic | Rocky Mount | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Self Management | Self Management as measured by the Patient Activation Measure which is an measure of their responses. The study team will plot a trajectory line using the Patient Activation Measure across all time points. The team is interested in knowing if this measure changes based on the patients self-management and his/her interaction with the health care provider. | baseline, 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 18 weeks, 24 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01937975 -
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
|
Phase 1 | |
Completed |
NCT03673696 -
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT02250001 -
Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C
|
N/A | |
Completed |
NCT03088917 -
'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
|
||
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Not yet recruiting |
NCT02865369 -
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
|
N/A | |
Recruiting |
NCT02638233 -
Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy
|
Phase 4 | |
Not yet recruiting |
NCT02511496 -
Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia
|
N/A | |
Not yet recruiting |
NCT01949168 -
A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
|
Phase 2 | |
Completed |
NCT02788682 -
Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy
|
N/A | |
Completed |
NCT01439776 -
Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients
|
Phase 4 | |
Recruiting |
NCT01360892 -
Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
|
N/A | |
Recruiting |
NCT01360879 -
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
|
N/A | |
Completed |
NCT00968357 -
Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed
|
Phase 2 | |
Terminated |
NCT00962936 -
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
|
Phase 1/Phase 2 | |
Recruiting |
NCT01178749 -
Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments
|
N/A | |
Recruiting |
NCT00575627 -
Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels
|
Phase 4 | |
Completed |
NCT00537407 -
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
|
Phase 2 | |
Recruiting |
NCT00370617 -
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance
|
Phase 4 | |
Completed |
NCT01684787 -
Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients
|
Phase 4 |